BJMO - volume 8, issue 5, november 2014
M. Peeters MD, PhD, K. Papadimitriou MD, PhD
From 26 till 30 September 2014, the 30th yearly ESMO meeting took place in Madrid. The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ This report will highlight the key studies presented during the meeting, with special focus on gastrointestinal cancer.
(BELG J MED ONCOL 2014;8(4):158–62)
Read moreBJMO - volume 6, issue 2, april 2012
T. Vandamme MD, PhD, V. Deschoolmeester PhD, P. Pauwels MD, PhD, M. Peeters MD, PhD
Targeted therapy with bevacuzimab, cetuximab and panitumumab has expanded the treatment options in metastatic colorectal cancer. Predictive tumour markers for treatment with targeted therapy that have been suggested are Epithelial Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR) expression, KRAS mutation and BRAF mutation status, loss of PTEN and PIK3CA mutation status. Of these, only KRAS has made it into clinical practice. KRAS mutation is a negative predictor for response to cetuximab EGFR inhibitors. No predictive tumour marker for bevacizumab has been identified. In this review, the current evidence on KRAS, BRAF, PTEN, PIK3CA, EGFR and VEGFR expression as predictive tumour markers for targeted therapy is reviewed. (BELG J MED ONCOL 2012;6:52–57)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
